NFATC3 and liposarcoma: Stimulating the MAPK pathway is known to increase the tumour staging and is associated with poor prognosis in liposarcoma such as dedifferentiated liposarcoma [133] while activating NFATC3 was previously found to promote the growth and migration of tumours such as glioma [134].